Psychedelic research breakthroughs face profit-driven roadblocks, warns top psychiatrist

Dr. Gabriella Gobbi, a leading psychiatrist at McGill University, has spent over a decade exploring groundbreaking treatments for mental health disorders. Her team's work on psychedelic substances like psilocybin and LSD shows real promise for depression and anxiety. Yet, she warns that profit-driven investment models are slowing down progress in psychiatric drug development.

Beyond research, Gobbi also highlights deep-rooted gender inequities in academic science. She calls for systemic changes to support women researchers, who often face extra burdens tied to caregiving and bias.

Since 2013, Gobbi's lab has launched five clinical trials on psychedelics, including studies on psilocybin and LSD for mood disorders. Trials like NCT02584370 (2015) and NCT03866174 (2019) reflect her team's push to turn early findings into real treatments. Their work extends to other substances, such as DMT and 5-MeO-DMT, aiming to unlock new therapeutic pathways.

Her research spans from molecular neuroscience to patient care, a philosophy she calls *bench-to-bedside*. One key discovery involved the melatonin MT2 receptor, which plays a crucial role in regulating deep sleep and easing neuropathic pain. This work exemplifies how basic biology can directly inform clinical practice. But translating these discoveries into widely available treatments remains a challenge. Public grants often fund early-stage research, yet moving compounds through trials depends on private investors demanding high returns. This financial pressure creates a bottleneck, leaving potentially affordable therapies stuck in early development. Gobbi's own career path underscores another hurdle in academia. She stepped into her professorship without formal training in leadership or grant writing, exposing gaps in institutional support. Now, she advocates for reforms to help women scientists thrive without facing unfair expectations or systemic barriers.

Gobbi's research offers hope for better mental health treatments, but financial and structural obstacles stand in the way. Without changes to how psychiatric drugs are funded, many promising therapies may never reach patients. Her call for gender equity in science also points to broader reforms needed to sustain innovation in medicine.